Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: Results of a double-blind, placebo-controlled trial

C. B. Taylor, C. Hayward, R. King, A. Ehlers, J. Margraf, Richard J Maddock, D. Clark, W. T. Roth, W. S. Agras

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Seventy-nine patients with panic disorder were randomized to an 8-week double-blind treatment with alprazolam, imipramine, or placebo. Patients kept daily records of panic attacks, activity, anxiety, sleep, and medication use. Weekly measures of anxiety, depression, somatic symptoms, fears, avoidance, disability, and improvement were obtained. All patients underwent a symptom-limited exercise treadmill and other cardiovascular measures. By physician and patient global assessment, patients receiving alprazolam or imipramine were significantly better than patients on placebo. The alprazolam effects were apparent by week 1; the imipramine effects by week 4. All groups showed significant reductions in anxiety, depression, somatic measures, and panic attack frequency. At 8 weeks, patients in the alprazolam group reported significantly less fear than patients in the other two groups. Subjects in the imipramine group showed a significant increase in heart rate and blood pressure.

Original languageEnglish (US)
Pages (from-to)112-118
Number of pages7
JournalJournal of Clinical Psychopharmacology
Volume10
Issue number2
StatePublished - 1990

Fingerprint

Alprazolam
Imipramine
Panic Disorder
Placebos
Anxiety
Fear
Depression
Sleep
Heart Rate
Exercise
Blood Pressure
Physicians

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder : Results of a double-blind, placebo-controlled trial. / Taylor, C. B.; Hayward, C.; King, R.; Ehlers, A.; Margraf, J.; Maddock, Richard J; Clark, D.; Roth, W. T.; Agras, W. S.

In: Journal of Clinical Psychopharmacology, Vol. 10, No. 2, 1990, p. 112-118.

Research output: Contribution to journalArticle

Taylor, C. B. ; Hayward, C. ; King, R. ; Ehlers, A. ; Margraf, J. ; Maddock, Richard J ; Clark, D. ; Roth, W. T. ; Agras, W. S. / Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder : Results of a double-blind, placebo-controlled trial. In: Journal of Clinical Psychopharmacology. 1990 ; Vol. 10, No. 2. pp. 112-118.
@article{c5b15fa47bd24dd886f857b41f591ecc,
title = "Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: Results of a double-blind, placebo-controlled trial",
abstract = "Seventy-nine patients with panic disorder were randomized to an 8-week double-blind treatment with alprazolam, imipramine, or placebo. Patients kept daily records of panic attacks, activity, anxiety, sleep, and medication use. Weekly measures of anxiety, depression, somatic symptoms, fears, avoidance, disability, and improvement were obtained. All patients underwent a symptom-limited exercise treadmill and other cardiovascular measures. By physician and patient global assessment, patients receiving alprazolam or imipramine were significantly better than patients on placebo. The alprazolam effects were apparent by week 1; the imipramine effects by week 4. All groups showed significant reductions in anxiety, depression, somatic measures, and panic attack frequency. At 8 weeks, patients in the alprazolam group reported significantly less fear than patients in the other two groups. Subjects in the imipramine group showed a significant increase in heart rate and blood pressure.",
author = "Taylor, {C. B.} and C. Hayward and R. King and A. Ehlers and J. Margraf and Maddock, {Richard J} and D. Clark and Roth, {W. T.} and Agras, {W. S.}",
year = "1990",
language = "English (US)",
volume = "10",
pages = "112--118",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder

T2 - Results of a double-blind, placebo-controlled trial

AU - Taylor, C. B.

AU - Hayward, C.

AU - King, R.

AU - Ehlers, A.

AU - Margraf, J.

AU - Maddock, Richard J

AU - Clark, D.

AU - Roth, W. T.

AU - Agras, W. S.

PY - 1990

Y1 - 1990

N2 - Seventy-nine patients with panic disorder were randomized to an 8-week double-blind treatment with alprazolam, imipramine, or placebo. Patients kept daily records of panic attacks, activity, anxiety, sleep, and medication use. Weekly measures of anxiety, depression, somatic symptoms, fears, avoidance, disability, and improvement were obtained. All patients underwent a symptom-limited exercise treadmill and other cardiovascular measures. By physician and patient global assessment, patients receiving alprazolam or imipramine were significantly better than patients on placebo. The alprazolam effects were apparent by week 1; the imipramine effects by week 4. All groups showed significant reductions in anxiety, depression, somatic measures, and panic attack frequency. At 8 weeks, patients in the alprazolam group reported significantly less fear than patients in the other two groups. Subjects in the imipramine group showed a significant increase in heart rate and blood pressure.

AB - Seventy-nine patients with panic disorder were randomized to an 8-week double-blind treatment with alprazolam, imipramine, or placebo. Patients kept daily records of panic attacks, activity, anxiety, sleep, and medication use. Weekly measures of anxiety, depression, somatic symptoms, fears, avoidance, disability, and improvement were obtained. All patients underwent a symptom-limited exercise treadmill and other cardiovascular measures. By physician and patient global assessment, patients receiving alprazolam or imipramine were significantly better than patients on placebo. The alprazolam effects were apparent by week 1; the imipramine effects by week 4. All groups showed significant reductions in anxiety, depression, somatic measures, and panic attack frequency. At 8 weeks, patients in the alprazolam group reported significantly less fear than patients in the other two groups. Subjects in the imipramine group showed a significant increase in heart rate and blood pressure.

UR - http://www.scopus.com/inward/record.url?scp=0025237681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025237681&partnerID=8YFLogxK

M3 - Article

C2 - 2187912

AN - SCOPUS:0025237681

VL - 10

SP - 112

EP - 118

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -